tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Heart Defects, Congenital D006330 20 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Translocation, Genetic D014178 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
HIV Infections D015658 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Ataxia D001259 20 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Hyperglycemia D006943 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Anemia D000740 21 associated lipids
Vomiting D014839 21 associated lipids
Erythema D004890 22 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Hypersensitivity D006967 22 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Obesity D009765 29 associated lipids
Kidney Diseases D007674 29 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Diarrhea D003967 32 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Heart Failure D006333 36 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Leukemia P388 D007941 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Psoriasis D011565 47 associated lipids
Precancerous Conditions D011230 48 associated lipids
Fatty Liver D005234 48 associated lipids
Thrombosis D013927 49 associated lipids
Osteosarcoma D012516 50 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Hyperlipidemias D006949 73 associated lipids
Leukemia D007938 74 associated lipids
Stomach Ulcer D013276 75 associated lipids
Alzheimer Disease D000544 76 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Atherosclerosis D050197 85 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Zhu L et al. [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients]. 2012 Yao Xue Xue Bao pmid:22993851
Wang M et al. Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection. 2002 Yan Ke Xue Bao pmid:15510746
Li S et al. Experiment study of retinal ultrastructure after intravitreal FK506. 2004 Yan Ke Xue Bao pmid:15124532
Xie H et al. Effect of topical FK506 used alone or combined with keratoplasty on patients with recurrent Mooren's corneal ulcer. 2006 Yan Ke Xue Bao pmid:17378150
Ma H et al. [The effect of FK506 on the proliferation of HRCECs]. 2006 Yan Ke Xue Bao pmid:17378157
Kagaya H et al. Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. 2006 Yakugaku Zasshi pmid:17139160
Tayama Y et al. [Influence of tacrolimus and ciprofloxacin on glucose metabolism]. 2007 Yakugaku Zasshi pmid:17978565
Naito T [Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice]. 2010 Yakugaku Zasshi pmid:21139397
Yamaguchi K et al. [Case of encephalopathy seemingly caused by tacrolimus at blood concentration near the upper limit of therapeutic range]. 2012 Yakugaku Zasshi pmid:22790031
Nagao K et al. [Drug development from natural fermentation products: establishing a manufacturing process which maximizes the potential of microorganisms]. 2010 Yakugaku Zasshi pmid:21048405
Fukudo M [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis]. 2007 Yakugaku Zasshi pmid:17603267
Sood S and Muthuraman A Activity of tacrolimus: an immunosuppressant, in pyloric ligation-induced peptic ulcer in the rat. 2009 Yakugaku Zasshi pmid:19952532
Tanaka H et al. [Discovery and development of a novel immunosuppressant, tacrolimus hydrate]. 1997 Yakugaku Zasshi pmid:9306728
Muraki Y [Factors affecting the pharmacokinetics after living donor liver transplant]. 2012 Yakugaku Zasshi pmid:23023417
Iwamoto T et al. [Successful treatment by tacrolimus in two patients with Osserman's grade III intractable myasthenia gravis and elderly IIb]. 2004 Yakugaku Zasshi pmid:15067188
Uchida K et al. Pharmacokinetics of orally administered tacrolimus in lupus nephritis patients. 2010 Yakugaku Zasshi pmid:20046074
Niwa T et al. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. 2007 Yakugaku Zasshi pmid:17202802
Shimizu K Development of New Liposome Targeting Strategies for Application of Disease Therapies. 2017 Yakugaku Zasshi pmid:28049894
Tanaka Y et al. [Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. 2013 Yakugaku Zasshi pmid:23328499
Li J et al. [Regulatory effect of FK506 on the expression of CD152 and PD-1 in the liver allo-recipients]. 2008 Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi pmid:18177621
He QH et al. [The role of superantigen SEB-induced immunotolerance in the immune privileged site]. 2003 Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi pmid:15132898
Bai YJ et al. [Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients]. 2008 Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi pmid:18845086
Pan ZX et al. [IL-18 expression in whole blood cell cultures from active lupus nephritis and the inhibitory effects of FK506, cyclosporin A and dexamethasone]. 2004 Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi pmid:15555450
Imamura R et al. ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: a case report. 2006 Xenotransplantation pmid:16623807
Song Z et al. Tacrolimus inhibits discordant islet xenograft rejection: a study in the pig-to-rat model. 2003 Xenotransplantation pmid:14617270
Balamurugan AN et al. Effect of various immunosuppressive monotherapies on survival and histopathology of monkey islet xenografts in rats. 2007 Xenotransplantation pmid:17669173
Miki T et al. Hamster-to-rat bone marrow xenotransplantation and humoral graft vs. host disease. 2001 Xenotransplantation pmid:11472629
Tachibana A et al. Repopulation of the immunosuppressed retrorsine-treated infant rat liver with human hepatocytes. 2013 Jul-Aug Xenotransplantation pmid:23683097
Zhou YN et al. Effect of amlodipine on the pharmacokinetics of tacrolimus in rats. 2013 Xenobiotica pmid:23312000
Picard N The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on "Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus". 2013 Xenobiotica pmid:23339626
Fujiyama N et al. Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. 2009 Xenobiotica pmid:19274604
Tata PN et al. Species-dependent hepatic metabolism of immunosuppressive agent tacrolimus (FK-506). 2009 Xenobiotica pmid:19604035
Zhang S et al. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. 2012 Xenobiotica pmid:22106961
Ogawa K et al. A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. 2013 Xenobiotica pmid:23153054
Lu XF et al. Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice. 2017 Xenobiotica pmid:27533047
Zhu L et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. 2015 Xenobiotica pmid:25869250
Lampen A et al. Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. 1998 Xenobiotica pmid:9622846
Jeong H and Chiou WL Role of P-glycoprotein in the hepatic metabolism of tacrolimus. 2006 Xenobiotica pmid:16507509
Patel CG et al. Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. 2013 Xenobiotica pmid:22934787
Chitnis SD et al. Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. 2013 Xenobiotica pmid:23278282
Miura M et al. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. 2005 Xenobiotica pmid:16012079
Niioka T et al. Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis. 2015 Xenobiotica pmid:26189776
Gupta AS et al. Pyoderma Gangrenosum of the Scalp: A Rare Clinical Variant. 2018 Wounds pmid:29481333
Kiyama T et al. Tacrolimus enhances colon anastomotic healing in rats. 2002 Sep-Oct Wound Repair Regen pmid:12406167
Song JL et al. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation. 2016 World J. Gastroenterol. pmid:26877618
Provenzani A et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. 2013 World J. Gastroenterol. pmid:24409044
Jia JJ et al. ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation. 2014 World J. Gastroenterol. pmid:25170223
Kawakami K et al. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. 2015 World J. Gastroenterol. pmid:25684955
Okan G et al. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. 2008 World J. Gastroenterol. pmid:18698687
Buchholz BM et al. Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients. 2018 World J. Gastroenterol. pmid:30065563